Studies

Our team of professional researchers has conducted over 100 studies benefiting many areas of medicine. By moving quickly on new studies, enrolling patients swiftly and gathering precise data, our team ensures sponsors get the most responsive, accurate trials possible. Whether conducting simple or highly complex studies, our team is as trusted as it is experienced.
 

Active Studies

  • A phase III, randomized, observer-blind, placebo-controlled, multicenter, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of a vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 50 years and older. 
  • A phase III, randomized, observer-blind, placebo-controlled, multicenter, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of a vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 70 years and older. 
  • Effect of an oral product medication on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities. A randomized, double-blind, placebo controlled, parallel group, multicenter, multi-national trial with stratification of subject to either 56 or 160 weeks of treatment based on pre-diabetes status at randomization. 
  • A long-term extension study of an oral product medication in combination with an oral product medication for subjects with gout completing an efficacy and safety study of an oral product medication and an oral product medication.  
  • A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the efficacy, safety and tolerability of combinations of an oral product medication and an oral product medication compared to an oral product medication and an oral product medication monotherapy in the treatment of overactive bladder. 
  • A randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study to evaluate the long-term safety and efficacy of combination of an oral product medication and an oral product medication compared to an oral product medication and an oral product medication monotherapy in subjects with overactive bladder.  
  • A phase 3, randomized, double blind, multicenter, placebo controlled study to evaluate the efficacy and safety of an oral product medication 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in subjects with gout.  
  • A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of product medication administered orally for 8 weeks to adult outpatients with opioid-induced constipation receiving chronic opioid treatment for non-cancer pain.
  • A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily product medication,  orally as add on to basal insulin in elderly Type 2 Diabetes mellitus patients with insufficient glycemic control.
     

Completed Studies

  • A randomized, double-blind, double-dummy, multicenter, parallel group study to assess the efficacy and safety of an oral product medication versus a product medication. 
  • A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the efficacy and safety of an oral product medication given either as a single oral dose of 640 mg or 320 mg once daily for three days versus oral product medication 250 mg twice a day for three days in the treatment of uncomplicated urinary tract infections (UTI) in female patients.
  • An open, non comparative multicenter study to assess the efficacy and safety of an oral product medication 125 mg twice daily for 7 days for the treatment of bacterial community acquired pneumonia in adults.  
  • A randomized, double-blind, double-dummy, multicenter, parallel group study to assess the effectiveness and health economic impact of an oral product medication 320 mg once daily for 5 days versus an oral product medication 500mg twice daily for 7 days for the treatment of acute exacerbation of chronic bronchitis (AECB).  
  • A 24 week randomized, open label study of health care resource use, quality of life and productivity with an oral product medication mg twice daily versus traditional therapy in females with non-constipated Irritable Bowel Syndrome.  
  • An oral cardiovascular medication versus an oral product medication for the treatment of Hypertension.
  • Prospective, randomized, double-blind, multicenter, comparative trial to evaluate the efficacy and safety of an oral product medication once daily extended release 500 mg tablets QD for 3 days versus conventional an oral product medication 250 mg tablets BID for 3 days in the treatment of patients with uncomplicated urinary tract infection.
  • Randomized, open-label, multicenter trial of the safety and effectiveness of an oral product medication and an oral product medication in outpatients with respiratory tract infections in usual care settings.
  • A multi-centered, phase IV post marketing, prospective, randomized, double-blind study comparing an oral product medication 40 mg once daily versus an oral product medication 30 mg twice daily in symptoms control of subjects with persistent symptoms of Gastroesophageal Reflux Disease while 30 mg once daily of an oral product medication therapy.  
  • Clinical utility of an oral product medication to improve concomitant cardiovascular risk factors of Hyperlipidemia and Dyslipidemia. 
  • A randomized, double-blind, placebo-controlled, multicenter, phase III study of an oral product medication 20 mg in the primary prevention of cardiovascular events among subjects with low levels of LDL-Cholesterol and elevated levels of C-Reactive Protein. 
  • A multi-center, randomized, double-blind, parallel group trial to compare the efficacy and safety of fixed-dose an oral product medication combination therapy to an oral product medication and an oral product medication in drug naïve subjects with Type II Diabetes mellitus.  
  • A double-blind, randomized, prospective, study to evaluate adjunctive an oral product medication versus adjunctive placebo in Generalized Anxiety Disorder sub-optimally responsive to standard psychotropic therapy.  
  • A double-blind, randomized prospective trial to evaluate the efficacy and safety of adjunctive an oral product medication versus placebo in subjects with major depressive disorder with suboptimal response to standard antidepressant therapy.  
  • A phase III multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of an oral product medication Extended Release tablets in the treatment of patients with Postherpetic Neuralgia.  
  • A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety an oral product medication and an oral product medication after 80 weeks of treatment. 
  • Prospective observational study to evaluate physical performance and quality of life in older long stay nursing home residents with Chronic Kidney Disease with and without Anemia. 
  • A phase II, double-blind randomized, placebo-controlled, parallel group, multicenter study to evaluate daily treatment with an oral product medication in subjects with Type 2 Diabetes. 
  • A randomized, open-label, blinded-endpoint, parallel-group trial of GI safety of an oral product medication compared with non-selective non steroidal anti-inflammatory drugs (NSAIDS) in Osteoarthritis patients.  
  • A randomized, double-blind, placebo-controlled study of an oral product medication in the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D).
  • An open-label, roll-over safety study of an oral product medication in the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D).
  • A phase III, randomized, double blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist an oral product medication in subjects with symptoms of overactive bladder.  
  • A phase III, randomized, double blind, parallel group, active controlled, multicenter long-term study to assess the safety and efficacy of the beta-3 agonist an oral product medication (50 mg qd and 1000 mg qd) in subjects with symptoms of overactive bladder.  
  • A randomized, double-blind, double-dummy trial of two sustained release formulations of an oral product medication compared to placebo in subjects with acute, painful, musculoskeletal spasm of the lower back. 
  • A randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of an oral product medication 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors.  
  • A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous product medication with oral adjusted-dose of product medication in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation. 
  • A Randomized, Double-blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-administration of a Triple Combination Therapy of an oral product medication, an oral product medication and an oral product medication in Subjects with Hypertension. 
  • A Phase III, active (an oral product medication) controlled, randomized, double-blind, parallel-arm study to evaluate efficacy and safety of an oral product medication in preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 
  • A pilot study for glycemic effects of an oral product medication compared with an oral product medication extended release and compared with an oral product medication in hypertensive patients with Type 2 Diabetes mellitus.  
  • Rotavirus gastroenteritis in a long-term care population.  
  • A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of an oral product medication (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) administered orally once daily over 12 weeks compared double blind to placebo with an additional open-label an oral product medication arm in type 2 diabetic patients with insufficient glycemic control despite an oral product medication therapy.  
  • A 78 week open label extension to trials assessing the safety and efficacy an oral product medication as monotherapy or in combination with an oral product medication in Type 2 Diabetic patients.  
  • A phase III, randomized, double-blind, placebo-controlled, parallel-group trial of an oral product medication administered orally for 12 weeks followed by a 4-week randomized withdrawal period in patients with chronic constipation.  
  • An open-label, long-term safety study of oral an oral product medication administered to patients with chronic constipation or irritable bowel syndrome with constipation. 
  • A multicenter, randomized, placebo-controlled, “factorial” design, 12-month study to evaluate the efficacy and safety of an oral product medication 25 mg/day and 50 mg/day co-administered with all registered an oral product medication strengths ranging from 10 mg to 80 mg in patients with primary hypercholesterolemia.  
  • A phase IIIb, prospective, observer-blind, randomized, controlled, multicenter study to evaluate the immunogenicity and safety of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, absorbed compared to tetanus and diphtheria toxoid absorbed vaccine, when administered to adults aged 65 years or older.  
  • A double-blind, randomized, parallel, placebo-controlled, multicenter study evaluating the effect treatment with topically administered topical gel product medication in patients with urinary frequency, and urge and mixed urinary incontinence with predominance of urge incontinence episodes with an open-label extension.  
  • A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist an oral product medication (25 mg qd and 50 mg qd) in subjects with symptoms of Overactive Bladder.  
  • A multicenter, randomized, double-blind, active controlled, parallel group, phase III trial to evaluate the safety and efficacy of an oral product medication 10 mg in combination with an oral product medication as initial therapy as compared with an oral product medication 10 mg monotherapy and an oral product medication monotherapy in subjects with Type 2 Diabetes who have inadequate glycemic control.  
  • A Phase III, randomized, double-blind, placebo-controlled, parallel-group trial of an oral product medication administered orally for 26 weeks in patients with Irritable Bowel Syndrome with Constipation.  
  • A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of an oral product medication in patients with type 2 diabetes mellitus on background treatment with an oral product medication with or without an oral product medication.  
  • A phase II randomized, double-blind, dose-response efficacy and safety study of an oral product medication compared to placebo in subjects with primary hypercholesterolemia (familial and non-familial) or mixed Hyperlipidemia.
  • A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of an oral product medication in patients with Type 2 Diabetes  mellitus on background treatment with an oral product medication.  
  • A Phase III randomized, double-blind, placebo-controlled, parallel group efficacy and safety study of an oral product medication (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patients in combination with basal insulin therapy. 
  • A Phase III, randomized, double-blind, placebo-controlled, parallel group efficacy and safety study of an oral product medication 5 mg administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient glycemic control despite a therapy of an oral product medication in combination with an oral product medication. 
  • A randomized, double-blind, placebo-controlled, dose-ranging study of the safety and efficacy of an oral product medication in subjects with type 2 diabetes mellitus on stable an oral product medication monotherapy. 
  • A Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of an oral product medication in older adult patients with uncomplicated influenza. 
  • A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multicenter study to evaluate the efficacy, safety, and tolerability of an oral product medication in the treatment of patients with irritable bowel syndrome with diarrhea. 
  • Multinational, prospective, observational study to characterize and assess the burden of refractory gouty arthritis on patients over one year.  
  • A Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous product medication in subjects with uncomplicated acute influenza. 
  • An international, longitudinal, observational study of individuals with Attention-Deficit/Hyperactivity Disorder (ADHD). 
  • Effect of an oral product medication on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities.  A randomized, double-blind, placebo controlled, parallel group, multi-centre, multi-national trial with stratification of subject to either 56 or 160 weeks of treatment based on pre-diabetes status at randomization. 
  • Awareness, detection, and drug therapy in Type 2 Diabetes and Chronic Kidney Disease.  A cross-sectional evaluation of Type 2 Diabetes and associated Chronic Kidney Disease in the primary care setting.  
  • A multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 3 Trial to evaluate the safety and efficacy of an oral product medication in subjects with Type 2 Diabetes with inadequately controlled hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB). 
  • A multicenter, randomized, double-blind clinical trial to assess the efficacy and safety of an otic solution 0.3% plus an otic solution 0.025% compared to an otic solution 0.3% and to otic solution 0.025% in the treatment of Acute Otitis Media with Tympanostomy Tubes (AOMT) in pediatric patients.  
  • A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of an oral product medication 25 mg/ an oral product medication 5 mg and an oral product medication 10 mg/ an oral product medication 5 mg fixed dose combination tablets compared with the individual components an oral product medication 25 mg, an oral product medication 10 mg, and an oral product medication 5 mg) for 52 weeks in treatment naïve and metformin treated patients with type 2 diabetes mellitus with insufficient glycemic control.  
  • Validation of the Diabetic Peripheral Neuropathic pain impact measure: a patient-reported outcome measure of the impact of DPNP on functioning.  
  • Cross-sectional, observational study to evaluate COPD severity using spirometry and physician and patient assessments.
  • A phase 3 randomized, double-blind, multicenter, placebo-controlled, combination study to evaluate the efficacy and safety of an oral product medication and an oral product medication compared to an oral product medication alone at lowering serum uric acid and resolving tophi in subjects with tophaceous Gout. 
  • Efficacy and safety of an oral product medication versus placebo as add-on to existing diabetes medication in subjects with type 2 diabetes and moderate renal impairment. A 26-week double-blind placebo-controlled, randomized, multicenter, multi-national, parallel-group trial.  
  • A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of an oral product medication in the treatment of patients with diarrhea-predominant Irritable Bowel Syndrome.  
  • A phase 2, multi-center, randomized, double-blind, placebo-controlled, multiple-dose study to determine the safety and efficacy of orally administered an oral product medication in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS-D). 
  • A phase 3b, randomized, double-blind, placebo-controlled, parallel-group trial of an oral product medication administered orally for 12 Weeks to patients with Chronic Constipation and prominent abdominal bloating at baseline. 
  • A phase 2b multicenter, randomized, double-blind, placebo- and active‑controlled, parallel-group study to assess the pharmacodynamic response and safety and tolerability of three dose levels of an oral product medication injection following 20 weeks of once-weekly subcutaneous dosing in adult subjects with inadequately treated Type 2 Diabetes Mellitus. 
  • A phase 2, randomized, double-blind, double-dummy, placebo and active-controlled, multicenter, parallel group study to evaluate the efficacy and safety of an oral product medication in patients with Type 2 Diabetes Mellitus. 
  • A phase 4, randomized, double-blind, multicenter, parallel-group, active-controlled, dose-optimization safety and efficacy study of an oral product medication compared with an oral product medication with a placebo reference arm, in adolescents aged 13-17 years with Attention-deficit/Hyperactivity Disorder (ADHD).  
  • A 26-week trial comparing efficacy and safety of insulin /insulin BID and insulin OD plus insulin in subjects with type 2 Diabetes Mellitus treated with insulin in need of treatment intensification with mealtime insulin.  
  • A phase III, randomized, double-blind, clinical trial to study the efficacy and safety of an oral product medication (a fixed-dose combination [FDC] of an oral product medication and an oral product medication) for the treatment of patients with Type 2 Diabetes Mellitus (T2DM) with inadequate glycemic control on metformin monotherapy.  
  • A double-blind, randomized, placebo-controlled, phase 3 trial in patients with chronic idiopathic constipation to demonstrate the efficacy and safety of an oral product medication 5 m and 10 mg for 12 weeks followed by a 4-week withdrawal period.  
  • A phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of an oral product medication in adult subjects with uncomplicated influenza.  
  • A national, randomized, 12-Week, double-Blind, placebo-controlled study to assess the safety and efficacy of an oral product medication (3.0 and 6.0 mg) in patients with Chronic Idiopathic Constipation. 
 

GET CONNECTED

Ready to begin your next trial? Call us at (330) 334-6229 or Contact Us today!